Method for oxidative stress correction under conditions of ultraviolet irradiation

FIELD: medicine.

SUBSTANCE: laboratory rats receive daily oral administration of the herb infusion of corn grassworm at a rate of 5 ml/kg of mass 20 minutes before exposure to ultraviolet rays, under ultraviolet irradiation conditions. The infusion is obtained by infusion of 5 g of herbs for 200 ml of boiling water for 60 minutes.

EFFECT: method provides oxidative stress correction based on reduced content of lipid peroxidation products in irradiated rats and increased activity of antioxidant system with a shortened phytocorrection course.

3 tbl



Same patents:

FIELD: medicine.

SUBSTANCE: biocompatible implant (BI) made of magnetic material in a biocompatible matrix (BM) is placed loosely along a posterior surface of an injured spinal cord of an experimental animal (EA) The EA is immersed periodically into a constant magnetic field. Its magnetic vector is aligned with a craniocaudal direction of spinal tracts. The BM of the BI is animal or herbal gelatine, wherein ferromagnetic magnetite or ferromagnetic ferrite nanoparticles 18-42 wt % with a particle size of 2.0-38 nm and at a magnetic field intensity (N) of 5-10 mT are immobilised as a magnetic material of the BI. The magnetic exposure covering the traumatic spinal injuries involves the combined effect of the magnetic field of the BI and the external rotating magnetic field at a magnetic induction of 0.15-0.35 T. The external magnetic exposure frequency is 1 or 2 times a day; the length is from 2 to 8 minutes per one session; the number of sessions is from 2 to 4. Animal gelatine in the BM of the BI can represent agar-agar, whereas herbal gelatine is pectin. The BM of the BI can additionally contain polyamines contributing to cell growth and proliferation, e.g. spermine or spemidine, in an amount of 1-5 wt %.

EFFECT: method enables recovering the spinal cord function sufficiently completely in the distal direction from the injury region, providing the favourable conditions for the adequate neuroglial growth with recipient's long neuron penetration from the intact proximal portion of the spinal cord into the distal one to ensure its conductive function, reducing the cicatrisation within the spinal injury, and eliminating the cerebral tissue oedema.

3 cl, 8 ex

FIELD: medicine.

SUBSTANCE: to a laboratory animal - rat - carried out is a unilateral nephrectomy, denervation and delymphatisation of the second kidney. After that the renal artery and vein are clamped for 40-60 minutes. After carrying out the surgical operation the triple immunisation of the laboratory animal with a kidney antigen, obtained from the removed kidney is carried out by an adjuvant method. 5 weeks before the surgical operation sampling of bone marrow cells from the laboratory animal is carried out, a culture of multipotent mesenchymal stromal cells is obtained from them in vitro. The denervation and delymphatisation of the remaining kidney is carried out by the removal of the adventitia and cellular tissue, wrapping the ureter, renal artery and vein, in the area of the hiluses renalis at a distance of 7-10 mm and decapsulation of the kidney in the area of its medial edge 7-10 mm wide, extension from one pole of the kidney to the other with the capture of the area of its hiluses. To obtain the kidney antigen the safe kidney is applied and the content of protein in it is brought to 70 mg/ml. On 35-40 day after carrying out the surgical operation the obtained culture of the multipotent mesenchymal stromal cells is introduced to the same animal intravenously in a dose of 1.5-3.0 mln cells in 1 ml of physiological solution.

EFFECT: method makes it possible to create an adequate, available for execution model of chronic rejection in autologous kidneys in small laboratory animals with an accelerated development of visualised destructive post-transplantation processes.

1 ex, 1 tbl, 9 dwg

FIELD: medicine.

SUBSTANCE: chemical burn is simulated in laboratory rats. From the 5th day following the simulation, therapeutic agents are administered abdominally. That involves using cefotaxime 100 mg/kg for 7 days. Prednisolone is administered in a dose of 1 mg/kg for 3 days. 3% Xymedone is administered in a dose of 30 mg/kg once a day for 40 days.

EFFECT: effective treatment of burns of the oesophagus and stomach by fast recovery of the thickness of a muscular layer of the mucous tunic and prevention of cicatrisation.

1 tbl, 16 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment tests, namely to production tests of joint implants with a metal friction pair the state of which is assessed in the course of testing with using electric (electrically resistive) diagnostic techniques. The diagnostic technique for joint implants with the metal friction pair consisting in the fact that the implant is mounted in a test bench loaded with axial force; a lubricant layer is formed between surfaces of the implant components, and the physical characteristics of the surface layer of the components in the friction zone are measured. Small AC current is passed through the friction zone of the implant; a temporary function of complex impedance of the implant tribocoupling is recorded; it uses its active and reactive component parameters to show an actual thickness of the lubricant layer and a lubricant type prevailing in the tribocoupling and a friction regimen. The actual technical condition of the joint implant tribocoupling is assessed by a ratio of the time intervals when the active part of the complex impedance is more than the reactive part to the total measurement time.

EFFECT: invention provides shortening the test time, assessing the real time of the contact of the friction surfaces, increasing the produced valid signal power and noise stability, in obtaining the objective initial diagnostic information from the friction zone in order to predict a durability of the joint implant with the metal friction pair.

5 dwg

FIELD: medicine.

SUBSTANCE: stimulating the excised liver regeneration is ensured by a 70% hepatectomy into a laboratory animal on the second day of the experiment. A liver regeneration stimulator is presented by L-norvaline administered intragastrically in a daily dose of 10.0 mg/kg every 46 hours for the first 7 days of the experiment.

EFFECT: method provides the effective stimulation of the excised liver regeneration evidenced by reducing the animals' lethality, improved hepatic microcirculation, reduced manifestation of cytolysis and enhanced synthetic function of the liver.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: limb ischemia is simulated in a male Wistar rat anaesthetised with chloral hydrate in a dose of 250-300 mg/kg by the surgical removal of femoral, popliteal arteries and the front shin artery. That is followed by introducing a prepared mononuclear fraction of the autologous bone marrow in a dose of 4106 cells in an amount of 200 mcl. The above is introduced into the ischemic limb from two points in an amount of 100 mcl each. One point is found directly under the femoral arch paravasally within the anatomical position of collaterals of the inner iliac artery and its branches. The other point is located in the calf muscle on an anteriolateral surface of the midleg.

EFFECT: more effective experimental treatment ensured by stimulating the collateral blood flow in the ischemic limb and improving the arterial blood flow from the proximal to distal parts of the limb.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method consists in a single administration of a mixture consisting of a rat's homogenised myocardial tissue - 25%, egg albumin - 25% and Freund's adjuvant - 50%, into old male rats. The method involves administering in an amount of 0.3 ml into 5 injection points: intraperitoneally, into inguinal and axillary regions from the left and right.

EFFECT: being easy to reproduce and cost efficient, the method is effective for creating a model aiming at a possibility of studying the pathogenesis, preventing and treating cardiopathy.

2 dwg, 1 tbl, 1 ex

Phantom test // 2555129

FIELD: medicine.

SUBSTANCE: phantom test consists of two parts being a single whole. One part has a constant longitudinal height, while the other part has a continuously varying longitudinal height forming a wedge. On the side of the wedge, there are calibrated notches.

EFFECT: more accurate determination of the bone mineral density by X-ray images formed with the help of a general-application X-ray machine, and simplifying the design.

7 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to gastroenterology, pathologic physiology, and concerns simulating acute pancreatitis. To this effect, the method involves ligaturing the main truck of the excretory duct of the pancreas, administering an aggressive solution into the pancreatic duct system, and removing the ligature. The aggressive solution represents 1% chenodeoxycholic acid with 5% sodium hydrogen carbonate in an equal proportion in an amount of 0.3-0.5 ml at 10-15 mg/kg of the animal's body weight.

EFFECT: method enables developing a model of acute fatty, hemorrhagic or mixed pancreatitis in the animal that makes it applicable for improving the known methods for conservative and radical methods of treating.

15 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to ophthalmology, and concerns simulation in vivo of cortical cataract. That is ensured by a double-side surgical sympathectomy by excising a superior cervical sympathetic ganglion.

EFFECT: by simplicity and effectiveness of modulation, the method provides forming the cortical lens-form opacity, which is morphologically and immunohistochemically identical to lens cell changes in age-related lens opacity in a human.

6 dwg, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to selenium nanocomposites of natural hepatotrophic galactose-containing polysaccharide matrixes, representing water-soluble orange-red powders containing zerovalent selenium (Se0) nanoparticles sized 1-100 nm in the quantitative content of 0.5 - 60 wt %, possessing antioxidant activity for treating and preventing redox-related pathologies, particularly for treating toxic liver damage, to a method for producing and to an antioxidant agent containing the above nanocomposites.

EFFECT: invention provides the targeted agent delivery to liver cells, as well as higher agent accessibility and lower toxic action of selenium.

7 cl, 11 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: method involves chelation of ferric (III) ions both in vivo, and in vitro with using 2-ethyl-6-methyl-3-hydroxypyridine succinate (Mexidol) to produce a stable stained complex having a high molecular weight and a complex (organic-inorganic) composition not identified among the known compounds.

EFFECT: high effectiveness of the chelation process and low toxicity of Mexidol that makes it promising for biomedical application.

4 dwg, 3 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to field of organic chemistry, namely to novel compound - 5(6)-nitro-1-(thietanyl-3)-2-ethoxybenzimidazole, inhibiting peroxidation of lipids.

EFFECT: novel compound, possessing useful biological properties, has been obtained.

2 cl, 1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention represents a mixture of two structural isomers: 2,6-di(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-4-methylphenol and its diastereomers, and 2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-6-(2,2,1-trimethylbicyclo[2.2.1]hept-5-yl)-4-methylphenol, and their diastereomers with the ratio of the first and second structural isomer isomers from 60:40 wt % to 95:5 wt %.

EFFECT: extension of the arsenal of means, possessing simultaneously haemorheological, anti-aggregate, anti-thrombogenic, retinoprotecting, endothelium-protecting, neuroprotecting, anti-arrhythmia and anti-ischemic activity, enhancing the cerebral blood flow.

4 dwg, 20 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: what is presented is using Histochrom (same as echinochrome A or pentahydroxyethyl naphthoquinone) as an agent able to prevent pulmonary fibrosis developed under cytostatic agents. The invention can be used for the pharmacological prevention and correction of the pulmonary tissue disorders caused by administering the cytostatic agents.

EFFECT: preventing hypertrophy of interalveolar connective tissue in the lungs associated with administering bleomycin.

4 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: drops possessing antiviral and immunomodulatory effects characterised by the fact that they represent a 95% ethanol infusion of wild strawberry leaves and fruit specified in: red raspberry fruit, mountain ash fruit, bilberry fruit, blood-red hawthorn fruit, cinnamon rose fruit; 15-25 mg of the substance in 1 ml of the infusion.

EFFECT: drops possess pronounced antiviral and immunomodulatory effects.

15 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: melanin having water-solubility of at least 80% and an paramagnetic centre concentration of at least 81017 spin/g is administered orally into the animals having been exposed to the radiation in a dose high enough to cause a spinal radiation injury; melanin is administered after dissolved in distilled water in the effective concentration. Melanin water is used as drinking water for the mice having been exposed to single and fractionated acute radiation, which is able to cause acute radiation disease. Melanin water is taken from the 1st to 30th day following the single radiation, or from the 1st day of the fractionated radiation to the 30th day on completion of the radiation.

EFFECT: higher survival rate, faster recovered haemopoiesis, body weight and orientation and motion activity.

7 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention provides a composition having antioxidant properties in the form of a tablet, comprising an active agent based on nicotinamide adenine dinucleotide in reduced form (NADH) and inert filling agents, characterised by that the active ingredient is a complex which is a mixture of 10 wt % NADH with 63 wt % vegetable fats, 17 wt % beeswax and 10 wt % chlorophyll, and the inert filling agents are in the form of microcrystalline cellulose, Macrogol 6000, intense sweetener and a food flavourant.

EFFECT: invention provides a new tablet form of NADH.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to a pharmaceutical composition with anti-ischemic and antioxidant activity in the form of tablets or capsules, and a method for preparing it. The composition contains 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid in an amount of 40 to 80 wt %, an amino-containing compound and pharmaceutically acceptable excipients. The amino-containing compound is specified in a group of trometamol, methyl glucamine and L-lysine; 1 mole of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid is accounted for 0.05 to 0.25 mole of the above amino-containing compound. The composition also contains lactose, microcrystalline cellulose, calcium stearate and other pharmaceutically acceptable excipients. According to the method for preparing the composition, taking 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid and amino-containing compound in molar ratio 1:0.05 to 1:0.25, pre-mixing, moisturising with a aqueous or alcohol solution of a binding agent, adding pharmaceutically acceptable excipients in such an amount to provide the content of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid from 40 to 80 wt %, granulating the mixture, drying and producing tablets or capsules according to the known technique.

EFFECT: implementing the above application.

6 cl, 7 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: claimed is the application of 5(6)-nitro-1-(1,1-dioxothietanyl-3)-2-chlorobenzimidazole of formula (I) , earlier known as the means with broncholytic and spasmolytic activity, as the means, inhibiting peroxide oxidation of lipids.

EFFECT: realisation of the claimed purpose.

1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely represents composition, which contains mixture of particles of hydrophobic silicon dioxide aerogel, which have specific area of surface per weight unit (Sw) in range from 500 to 1500 m2/g and size, expressed in form of volume mean diameter (D[0.5]), in range from 1 to 1500 mcm, and at least one first linear silicone oil, which has viscosity higher than 50 mm2/s, and at least second and third linear silicone oils, and each of them has viscosity lower than or equal 50 mm2/s.

EFFECT: mixture of particles of silicon dioxide aerogel and linear oils provides possibility of obtaining compositions, which provide comfort and smoothness of skin after application and have dullness and "soft focus"-adding properties.

23 cl, 8 ex